Odontogenesis-associated phosphoprotein (ODAPH)

Odontogenesis-associated phosphoprotein (ODAPH) is a small, secreted phosphoprotein specifically expressed by ameloblasts during the transition and maturation stages of amelogenesis, the process of enamel formation in teeth[1][2][3][5]. It was discovered as a causative gene for autosomal recessive amelogenesis imperfecta, a heritable disorder characterized by hypomineralized and thin enamel, and was formerly known as C4orf26[1][2][5]. ODAPH is phosphorylated by the kinase FAM20C, a post-translational modification important for its secretion and likely its functional role in the extracellular enamel matrix[2]. In vitro and in vivo studies indicate that phosphorylated ODAPH promotes hydroxyapatite nucleation, implicating it as an initiator or regulator of enamel mineralization[1][2]. Truncations or loss-of-function mutations in ODAPH result in defective enamel structure, demonstrating its essential function in tooth development[1][3]. There is no evidence that ODAPH is a classic therapeutic drug target (e.g., receptor, enzyme), and currently there are no known drugs, biomarkers, or safety concerns associated with targeting ODAPH[1][2][3][5].

Other names

C4orf26FLJ23657AI2A4uncharacterized protein C4orf26amelogenesis imperfecta type IIA4Gm1045 (mouse)odontogenesis associated phosphoprotein